%0 Journal Article %A Annette C. Toledano %T The Acute Treatment of Migraine with Low-Dose Naltrexone/Acetaminophen Combinations and Each Component: Findings of a Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial %D 2021 %R 10.1101/2021.03.22.21254145 %J medRxiv %P 2021.03.22.21254145 %X We tested two low-dose naltrexone/acetaminophen combinations and each component in the acute treatment of migraine. The patients use a single-dose of the study medication for a moderate or severe pain intensity migraine attack. Patients were adults with migraine with or without aura experiencing 2 to 20 (average 6.4) monthly migraine days. The co-primary endpoints were pain-freedom and absence of prospectively-identified most bothersome migraine-associated symptom 2 hours after dosing. We randomized 92 patients; 72 completed the study (mean age, 43 years; 75% women). Pain-freedom at 2 hours was 10.2% higher than placebo with naltrexone 2.25 mg/acetaminophen 325 mg, 10.9% with naltrexone 3.25 mg/acetaminophen 325 mg, 17.3% with naltrexone 2.25 mg, and 31.3% with acetaminophen 325 mg. The treatment groups’ migraine burden was unbalanced due to randomized patients’ uneven study completion. The acetaminophen group had the lowest migraine burden, giving its results lower credibility.Saliently, Low-dose naltrexone alone (n=19) had a 17.3% higher response rate than placebo (n=17) for headache pain-freedom at 2 hours. The naltrexone and the placebo groups were the largest and had a balanced disease burden, implying higher credibility to the naltrexone group results. We found low-dose naltrexone/acetaminophen, low-dose naltrexone, and acetaminophen had higher response rates than placebo in treating headache pain.The most commonly reported adverse events were sedation, nausea, and dizziness. We postulate that naltrexone’s toll-like receptor (TLR4) antagonism properties prevent pro-inflammatory cytokines’ production, leading to the trigeminal ganglion neurons becoming “overactive” and migraine. Although this trial used low-dose naltrexone (defined as 1 – 5 mg/day), we postulate mid-dose naltrexone (MDN) (defined as 6 – 10 mg/day) may offer a greater acute migraine control.Competing Interest StatementDr. Annette Toledano reports she is the founder/medical director of Allodynic Therapeutics, LLC and the inventor/patent holder of several naltrexone/acetaminophen patents. Allodynic Therapeutics is a clinical-stage, specialty Biopharmaceutical Company focused on painful conditions with high unmet needs. Clinical TrialClinicalTrials.gov Identifier: NCT03061734Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Schulman Associates IRB (now Advarra).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not available %U https://www.medrxiv.org/content/medrxiv/early/2021/04/01/2021.03.22.21254145.full.pdf